A 2020 systematic review and meta-analysis assessing the safety and efficacy of osimertinib in treating NSCLC based on overall survival (OS), PFS, treatment response, and adverse events (AEs), that included 47 studies, found osimertinib to be associated with an improved OS and PFS in all patients, including when compared to other EGFR-TKIs or chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.